Join for free and get access to the buyside
Get insights from the world's most influential hedge fund investors direct to your inbox
- © 2025 Buyside Digest
- Privacy Policy
- Disclaimer
- Sitemap
- Terms of Service
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Keywords/Themes | Theme Commentary | Pitches | Letter |
|---|---|---|---|---|---|---|---|---|---|
| 2025 Q2 | Jun 30, 2025 | Clark Street Value | - | -3.6% | ACR, ATHA, CKX, CMCT, CRGX, DNB, EHAB, ELEV, ENZ, EPIX, GRBK, HHH, HLVX, IGT, IKNA, INBX, IOR, KRON, KROS, LMNR, ME, MREO, MURA, NSTS, PARR, RPTX, SEG, SHCO, THRD | activism, catalysts, Event-Driven, liquidation, special situations | The portfolio review centers on special situations such as liquidations, strategic alternatives, spinoffs, and activist-driven outcomes. The manager focuses on downside-protected setups where cash, assets, or catalysts limit risk. Event-driven value is positioned as attractive amid broad market overvaluation. | IGT EHAB SHCO NSTS IOR CKX THRD RPTX MURA EPIX ATHA |
View |
| 2025 Q1 | Apr 24, 2025 | Tidefall Capital Management | -5.6% | -5.6% | KROS | asymmetric returns, Balance Sheet Strength, Biotech Value, Geopolitical Risk, Trade Policy | The letter focuses on rising geopolitical fragmentation and U.S.-led trade disruption as structural forces reshaping global supply chains, capital allocation, and investor assumptions. While acknowledging near-term recession risk and confidence shocks, Tidefall emphasizes bottom-up stock selection and selectively exploiting dislocations, particularly in capital-starved biotech companies trading below net cash. The portfolio reflects caution toward macro instability while positioning for optionality where balance sheets, activist involvement, and asymmetric outcomes skew returns favorably. | KROS |
View |
| Date | Pitch Type | Author | Company | Industry | Sub Industry | Bull / Bear | Stock Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|
| Jan 30, 2026 | Fund Letters | Trevor Scott | Keros Therapeutics Inc. | Health Care | Biotechnology | Bull | NASDAQ | Activism, balance sheet, biotechnology, net cash, royalties | View Pitch |
| Jan 23, 2026 | Twitter / X | @Lord_of_Biotech | Keros Therapeutics | Health Care Services | Biotechnology | Bull | NASDAQ | Burn, Calculation, cash, Clinical, Deal, net cash, Takeda, While Strategic | View Pitch |
| Oct 27, 2025 | Substack | Toff Cap Monday Monitor | Keros Therapeutics, Inc. | Health Care | Biotechnology | Neutral | biopharmaceutical, capital return, cash reserves, hematological disorders, Keros Therapeutics, musculoskeletal disorders, R&D funding, shareholder liquidity, strategic review, tender offer | View Pitch |
| Manager Name | Fund Name | Fund AUM | Invested Value | Portfolio Weight | Shares Owned | Shares Bought / Sold During Quarter | % Bought / Sold During Quarter | % of Shares Outstanding Owned |
|---|---|---|---|---|---|---|---|---|
| No investor data available. | ||||||||